Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDiTeos Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 4 | -$1.35 | -$0.70 | -$1.00 |
| Q2 2025 | 2 | -$1.03 | -$1.03 | -$1.03 |
| Q3 2025 | 2 | -$0.97 | -$0.97 | -$0.97 |
| Q4 2025 | 2 | -$1.01 | -$1.01 | -$1.01 |
| Q1 2026 | 1 | -$0.93 | -$0.93 | -$0.93 |
| Q2 2026 | 1 | -$1.00 | -$1.00 | -$1.00 |
| Q3 2026 | 1 | -$1.04 | -$1.04 | -$1.04 |
| Q4 2026 | 1 | -$0.84 | -$0.84 | -$0.84 |
| Q1 2027 | 1 | -$1.20 | -$1.20 | -$1.20 |
| Q2 2027 | 1 | -$1.23 | -$1.23 | -$1.23 |
| Q3 2027 | 1 | -$1.11 | -$1.11 | -$1.11 |
| Q4 2027 | 1 | -$1.11 | -$1.11 | -$1.11 |
iTeos Therapeutics, Inc. Earnings Date And Information
iTeos Therapeutics, Inc. last posted its earnings results on Wednesday, March 5th, 2025. The company reported $-1.01 earnings per share for the quarter, topping analysts' consensus estimates of $-1.14 by $0.13. The company had revenue of 0 for the quarter and had revenue of 35.00 M for the year. iTeos Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-3.32 diluted earnings per share) and currently has a price-to-earnings ratio of -2.26. iTeos Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 4th, 2025 based on prior year's report dates.
iTeos Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/05/2025 | Q4 2024 | -$1.14 | -$1.08 | 0.06 | $800,000 | $0 |
| 11/12/2024 | Q3 2024 | -$1.18 | -$1.05 | 0.13 | $800,000 | $0 |
| 08/08/2024 | Q2 2024 | -$1.04 | -$0.18 | 0.86 | $1.00 M | $35.00 M |
| 05/10/2024 | Q1 2024 | -$1.02 | -$1.07 | -0.05 | N/A | $0 |
| 03/06/2024 | Q4 2023 | -$1.03 | -$0.85 | 0.18 | $12.47 M | $-11,303,000 |
| 11/07/2023 | Q3 2023 | -$1.20 | -$0.90 | 0.3 | N/A | $0 |
| 08/08/2023 | Q2 2023 | -$1.03 | -$0.96 | 0.07 | N/A | $0 |
| 05/10/2023 | Q1 2023 | -$0.99 | -$0.44 | 0.55 | N/A | $12.60 M |
| 03/15/2023 | Q4 2022 | $0.33 | $0.57 | 0.24 | N/A | $53.91 M |
| 11/10/2022 | Q3 2022 | $0.10 | $0.03 | -0.07 | $41.64 M | $19.49 M |
| 08/10/2022 | Q2 2022 | $1.20 | $0.15 | -1.05 | $85.56 M | $41.72 M |
| 05/12/2022 | Q1 2022 | $0.80 | $1.82 | 1.02 | N/A | $152.52 M |
| 03/23/2022 | Q4 2021 | $1.28 | $5.26 | 3.98 | N/A | $240.50 M |
| 11/10/2021 | Q3 2021 | $4.95 | $1.98 | -2.97 | $6.50 M | $104.27 M |
| 08/11/2021 | Q2 2021 | N/A | -$0.75 | N/A | $3.91 M | $0 |
| 05/13/2021 | Q1 2021 | -$0.48 | -$0.39 | 0.09 | N/A | $0 |
| 03/24/2021 | Q4 2020 | -$0.42 | -$0.61 | -0.19 | N/A | $0 |
| 11/12/2020 | Q3 2020 | -$0.36 | -$0.44 | -0.08 | N/A | $0 |
| 09/01/2020 | Q2 2020 | -$0.47 | -$0.23 | 0.24 | N/A | $0 |
| 03/30/2020 | Q1 2020 | N/A | -$0.17 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
iTeos Therapeutics, Inc. Earnings: FAQ's
iTeos Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 4th, 2025 based offlast year's report dates.
In the previous quarter, iTeos Therapeutics, Inc. (:ITOS) reported $-1.01 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.14 by $0.13.
The conference call for iTeos Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for iTeos Therapeutics, Inc.'s latest earnings report can be read online.
iTeos Therapeutics, Inc. (:ITOS) has a recorded annual revenue of $35.00 M.
iTeos Therapeutics, Inc. (:ITOS) has a recorded net income of $-134,414,000.iTeos Therapeutics, Inc. has generated $-3.32 earnings per share over the last four quarters.
iTeos Therapeutics, Inc. (:ITOS) has a price-to-earnings ratio of -2.26 and price/earnings-to-growth ratio is 0.31.